GLUE
Monte Rosa Therapeutics Inc
10.30$
-2.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | +63.5% | |
| – | +645.8% | +297.0% | +301.5% | -27.3% | +30.5% | +2.9% | |
| – | – | – | – | – | – | +70.8% | |
| – | +219.3% | +143.5% | +48.8% | +23.5% | +15.7% | +16.4% | |
| – | +521.9% | +292.7% | +73.7% | +17.3% | +9.8% | +3.4% | |
| – | +243.7% | +165.3% | +54.2% | +22.0% | +8.4% | +14.1% | |
| – | – | – | – | – | – | – | |
| – | +800.0% | +11,855.6% | +249.8% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | -31.8% | -1,166.7% | – | – | +660.4% | -142.7% | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.